<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="Fn1">
  <label>1</label>
  <p id="Par4">After the adoption of the 
   <italic>Pandemic Influenza Preparedness Framework</italic> in 2011, the GISN was renamed the Global Influenza Surveillance and Response System (GISRS).
  </p>
 </fn>
 <fn id="Fn2">
  <label>2</label>
  <p id="Par5">Sedyaningsih et al. (
   <xref ref-type="bibr" rid="CR39">2008</xref>).
  </p>
 </fn>
 <fn id="Fn3">
  <label>3</label>
  <p id="Par6">It appears that the term “viral sovereignty” was originally coined by Holbrooke and Garrett (
   <xref ref-type="bibr" rid="CR26">2008</xref>).
  </p>
 </fn>
 <fn id="Fn4">
  <label>4</label>
  <p id="Par7">Ibid.</p>
 </fn>
 <fn id="Fn5">
  <label>5</label>
  <p id="Par8">See Lange (
   <xref ref-type="bibr" rid="CR31">2012</xref>).
  </p>
 </fn>
 <fn id="Fn6">
  <label>6</label>
  <p id="Par9">Gostin et al. (
   <xref ref-type="bibr" rid="CR21">1918</xref>).
  </p>
 </fn>
 <fn id="Fn7">
  <label>7</label>
  <p id="Par10">For examples of this portrayal of the viral sovereignty tale, see Vezzani (
   <xref ref-type="bibr" rid="CR45">2010</xref>).
  </p>
 </fn>
 <fn id="Fn8">
  <label>8</label>
  <p id="Par12">Convention on Biological Diversity 1992, Art. 1.</p>
 </fn>
 <fn id="Fn9">
  <label>9</label>
  <p id="Par14">Smith (
   <xref ref-type="bibr" rid="CR42">2012</xref>), Bollinger (
   <xref ref-type="bibr" rid="CR5">2015</xref>).
  </p>
 </fn>
 <fn id="Fn10">
  <label>10</label>
  <p id="Par15">World Health Organisation (
   <xref ref-type="bibr" rid="CR52">2015a</xref>).
  </p>
 </fn>
 <fn id="Fn11">
  <label>11</label>
  <p id="Par17">It is also worth noting the geographical link that is created through the naming conventions for human viruses. Marburg virus, Lassa fever, Ebola, Ross River virus, Barmah Forest virus, Middle Eastern Respiratory Syndrome virus, and Crimean-Congo haemorrhagic fever to name but a few, are all named after the places where the first cases appeared, or the virus was initially isolated. In recent times this has been identified as a “stigmatizing” practice that can result in reputational damage to the virus’ namesake (see World Health Organisation, “WHO issues best practices for naming new human infectious diseases” 2015 at 
   <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/news/notes/2015/naming-new-diseases/en/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.who.int/mediacentre/news/notes/2015/naming-new-diseases/en/</ext-link>) but it does demonstrate the connection of geographical location to virus samples that has existed well before the acknowledgement of sovereign rights over viruses.
  </p>
 </fn>
 <fn id="Fn12">
  <label>12</label>
  <p id="Par18">Cyranoski (
   <xref ref-type="bibr" rid="CR15">2003</xref>).
  </p>
 </fn>
 <fn id="Fn13">
  <label>13</label>
  <p id="Par19">As an aside, the media coverage of the Human Immunodeficiency Virus (HIV) discovery controversy between Robert Gallo (USA) and Luc Montagnier (France) in the mid to late-1980 sometimes referred French or U.S. virus samples, but this was really just shorthand for what were considered the samples belonging to the French or U.S. research teams. There is no sense from the literature or news reports from the time that these were considered the sovereign property of any nation state. It was, however, a matter of national pride, which did result in both French and U.S. government leaders holding meetings over the dispute. For more information on the Gallo and Montagnier HIV sample dispute, see Ranga (
   <xref ref-type="bibr" rid="CR35">2009</xref>) and Singer (
   <xref ref-type="bibr" rid="CR41">1989</xref>).
  </p>
 </fn>
 <fn id="Fn14">
  <label>14</label>
  <p id="Par21">‘Russia, China Cooperate in Fighting Infections-Karelova’ 
   <italic>ITAR</italic>-
   <italic>TASS Information Telegraph Agency of Russia</italic>, 17 September 2003.
  </p>
 </fn>
 <fn id="Fn15">
  <label>15</label>
  <p id="Par23">Yasuda (
   <xref ref-type="bibr" rid="CR62">2004</xref>).
  </p>
 </fn>
 <fn id="Fn16">
  <label>16</label>
  <p id="Par25">Ibid.</p>
 </fn>
 <fn id="Fn17">
  <label>17</label>
  <p id="Par27">Butler (
   <xref ref-type="bibr" rid="CR7">2005</xref>).
  </p>
 </fn>
 <fn id="Fn18">
  <label>18</label>
  <p id="Par29">Ibid.</p>
 </fn>
 <fn id="Fn19">
  <label>19</label>
  <p id="Par31">Ibid.</p>
 </fn>
 <fn id="Fn20">
  <label>20</label>
  <p id="Par32">Vietnam News Agency (
   <xref ref-type="bibr" rid="CR46">2005</xref>).
  </p>
 </fn>
 <fn id="Fn21">
  <label>21</label>
  <p id="Par33">Ibid.</p>
 </fn>
 <fn id="Fn22">
  <label>22</label>
  <p id="Par35">This document was originally available online at 
   <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/avian_influenza/guidelines/Guidance_sharing_viruses_specimens/en/index.html" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.who.int/csr/disease/avian_influenza/guidelines/Guidance_sharing_viruses_specimens/en/index.html</ext-link> however, since the dispute with Indonesia in 2007, the document is no longer accessible. See Sedyaningsih et al., above n 2, 21. The Third World Network reproduced the guidance document in Annex 1 to their briefing paper issued in May 2007 “Sharing of Avian Influenza Viruses” which can be accessed at 
   <ext-link ext-link-type="uri" xlink:href="https://web.archive.org/web/20120822191210/" xmlns:xlink="http://www.w3.org/1999/xlink">https://web.archive.org/web/20120822191210/</ext-link>, 
   <ext-link ext-link-type="uri" xlink:href="http://www.twnside.org.sg/title2/avian.flu/papers/avian.flu.twn.briefing.paper.may2007.doc" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.twnside.org.sg/title2/avian.flu/papers/avian.flu.twn.briefing.paper.may2007.doc</ext-link>.
  </p>
 </fn>
 <fn id="Fn23">
  <label>23</label>
  <p id="Par36">Third World Network (
   <xref ref-type="bibr" rid="CR44">2007</xref>, p 17).
  </p>
 </fn>
 <fn id="Fn24">
  <label>24</label>
  <p id="Par37">Ibid.</p>
 </fn>
 <fn id="Fn25">
  <label>25</label>
  <p id="Par39">World Health Organisation (
   <xref ref-type="bibr" rid="CR48">2005a</xref>).
  </p>
 </fn>
 <fn id="Fn26">
  <label>26</label>
  <p id="Par40">World Health Organisation (
   <xref ref-type="bibr" rid="CR50">2006</xref>).
  </p>
 </fn>
 <fn id="Fn27">
  <label>27</label>
  <p id="Par42">Nebehay (
   <xref ref-type="bibr" rid="CR34">2006</xref>).
  </p>
 </fn>
 <fn id="Fn28">
  <label>28</label>
  <p id="Par43">Ibid. It is interesting to note that in this same news report, Indonesian Health Minister (2004–2009) Dr. Siti Fadilah Supari, spoke positively about Chan’s appointment.</p>
 </fn>
 <fn id="Fn29">
  <label>29</label>
  <p id="Par44">Beck (
   <xref ref-type="bibr" rid="CR4">2006</xref>).
  </p>
 </fn>
 <fn id="Fn30">
  <label>30</label>
  <p id="Par46">Butler, above n 17.</p>
 </fn>
 <fn id="Fn31">
  <label>31</label>
  <p id="Par47">Third World Network, above n 23.</p>
 </fn>
 <fn id="Fn32">
  <label>32</label>
  <p id="Par48">Sedyaningsih et al., above n 2, 485.</p>
 </fn>
 <fn id="Fn33">
  <label>33</label>
  <p id="Par50">Fidler (
   <xref ref-type="bibr" rid="CR17">2008</xref>).
  </p>
 </fn>
 <fn id="Fn34">
  <label>34</label>
  <p id="Par51">World Health Organisation (
   <xref ref-type="bibr" rid="CR53">2015b</xref>, p. 1).
  </p>
 </fn>
 <fn id="Fn35">
  <label>35</label>
  <p id="Par52">Fidler, above n 33, 90.</p>
 </fn>
 <fn id="Fn36">
  <label>36</label>
  <p id="Par54">Sedyaningsih et al., above n 2, 484.</p>
 </fn>
 <fn id="Fn37">
  <label>37</label>
  <p id="Par55">Ibid.</p>
 </fn>
 <fn id="Fn38">
  <label>38</label>
  <p id="Par56">Ibid.</p>
 </fn>
 <fn id="Fn39">
  <label>39</label>
  <p id="Par58">Sedyaningsih et al., above n 2.</p>
 </fn>
 <fn id="Fn40">
  <label>40</label>
  <p id="Par59">Ibid., 485.</p>
 </fn>
 <fn id="Fn41">
  <label>41</label>
  <p id="Par60">Ibid., 487.</p>
 </fn>
 <fn id="Fn42">
  <label>42</label>
  <p id="Par61">The factors that led to Indonesia’s withdrawal of support for the GISN have been discussed at length elsewhere. See, for instance, Sedyaningsih et al., Hameiri (
   <xref ref-type="bibr" rid="CR22">2014</xref>).
  </p>
 </fn>
 <fn id="Fn43">
  <label>43</label>
  <p id="Par63">Caplan and Curry (
   <xref ref-type="bibr" rid="CR8">2007</xref>). Note that Caplan and Curry also say that Indonesia’s “strategy can be seen as innovative, perhaps even courageous”.
  </p>
 </fn>
 <fn id="Fn44">
  <label>44</label>
  <p id="Par64">Holbrooke and Garrett, above n 3.</p>
 </fn>
 <fn id="Fn45">
  <label>45</label>
  <p id="Par65">Bagley (
   <xref ref-type="bibr" rid="CR2">2018</xref>). Bagley’s article was referring to a separate issue (compulsory licensing) but it is cited here because it so elegantly details the moral obligation of domestic governments to provide for the health of its own citizens.
  </p>
 </fn>
 <fn id="Fn46">
  <label>46</label>
  <p id="Par67">Indonesia’s claim in 2007 might even be considered completely predictable in the context of the ABS discussions underway at other UN bodies (the United Nations Environment Programme and the Food and Agriculture Organisation).</p>
 </fn>
 <fn id="Fn47">
  <label>47</label>
  <p id="Par69">Convention on Biological Diversity, 
   <italic>List of Parties</italic> (2016). 
   <ext-link ext-link-type="uri" xlink:href="https://www.cbd.int/information/parties.shtml" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cbd.int/information/parties.shtml</ext-link>.
  </p>
 </fn>
 <fn id="Fn48">
  <label>48</label>
  <p id="Par71">Convention on Biological Diversity 1992, Art. 1.</p>
 </fn>
 <fn id="Fn49">
  <label>49</label>
  <p id="Par73">Ibid., Art. 15(1).</p>
 </fn>
 <fn id="Fn50">
  <label>50</label>
  <p id="Par75">Fidler noted that “State practice under CBD supports the conclusion that CBD does not apply to avian influenza virus. States parties to CBD have addressed avian influenza, not as a biological resource subject to CBD but as a threat to biological diversity”. Fidler, above n 33, 91.</p>
 </fn>
 <fn id="Fn51">
  <label>51</label>
  <p id="Par76">Rourke (
   <xref ref-type="bibr" rid="CR36">2017</xref>).
  </p>
 </fn>
 <fn id="Fn52">
  <label>52</label>
  <p id="Par77">In 1995 the COP to the CBD “reaffirm[ed]” that human genetic resources are outside the scope of the CBD, despite neatly fitting the definition of the term provided by the CBD. It reaffirmed this position at the adoption of the Nagoya Protocol in 2010. Convention on Biological Diversity, 
   <italic>Report of the Second Meeting of the Conference of the Parties to the Convention on Biological Diversity</italic> (1995) UNEP/CBD/COP/2/19 Decision II/11, Access to Genetic Resources (para 2); Convention on Biological Diversity, 
   <italic>Report of the Tenth Meeting of the Conference of the Parties to the Convention on Biological Diversity</italic> (2010) UNEP/CBD/COP/10/27 Decision X/1, Access to genetic resources and the fair and equitable sharing of benefits arising from their utilisation (para 5).
  </p>
 </fn>
 <fn id="Fn53">
  <label>53</label>
  <p id="Par78">The Nagoya Protocol is a voluntary and legally-binding supplementary agreement to the CBD. It was adopted by the Conference of the Parties to the CBD in 2010 and entered into force on 12 October 2014. It currently has 107 parties. See 
   <ext-link ext-link-type="uri" xlink:href="https://www.cbd.int/abs/nagoya-protocol/signatories/default.shtml" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cbd.int/abs/nagoya-protocol/signatories/default.shtml</ext-link> (accessed 12 October 2018).
  </p>
 </fn>
 <fn id="Fn54">
  <label>54</label>
  <p id="Par79">Convention on Biological Diversity 1992, Art. 15(5); Nagoya Protocol 2010, Art. 6(1).</p>
 </fn>
 <fn id="Fn55">
  <label>55</label>
  <p id="Par80">Convention on Biological Diversity 1992, Art. 15(3); Nagoya Protocol 2010, Art. 6(1).</p>
 </fn>
 <fn id="Fn56">
  <label>56</label>
  <p id="Par81">Convention on Biological Diversity 1992, Art. 15(4); Nagoya Protocol 2010, Art. 5(1).</p>
 </fn>
 <fn id="Fn57">
  <label>57</label>
  <p id="Par82">Nagoya Protocol, 2010, Art. 8(b).</p>
 </fn>
 <fn id="Fn58">
  <label>58</label>
  <p id="Par83">See, e.g., Nagoya Protocol 2010, Art. 10 “Global Multilateral Benefit-Sharing Mechanism”.</p>
 </fn>
 <fn id="Fn59">
  <label>59</label>
  <p id="Par84">Nagoya Protocol 2010, Art. 4(4).</p>
 </fn>
 <fn id="Fn60">
  <label>60</label>
  <p id="Par86">Seventieth World Health Assembly (
   <xref ref-type="bibr" rid="CR40">2017</xref>, 22–23).
  </p>
 </fn>
 <fn id="Fn61">
  <label>61</label>
  <p id="Par87">Ibid., 22.</p>
 </fn>
 <fn id="Fn62">
  <label>62</label>
  <p id="Par88">Ibid., 23.</p>
 </fn>
 <fn id="Fn63">
  <label>63</label>
  <p id="Par90">Hurlbut (
   <xref ref-type="bibr" rid="CR27">2017</xref>).
  </p>
 </fn>
 <fn id="Fn64">
  <label>64</label>
  <p id="Par92">U.S. Mission to the United Nations in Geneva, ‘U.S. Statement on Pandemic-Influenza Preparedness: Sharing of Influenza Vaccines and Access to Vaccines and Other Benefits’ Press Release 23 May 2007. 
   <ext-link ext-link-type="uri" xlink:href="https://web.archive.org/web/20090504014606/" xmlns:xlink="http://www.w3.org/1999/xlink">https://web.archive.org/web/20090504014606/</ext-link>, 
   <ext-link ext-link-type="uri" xlink:href="http://geneva.usmission.gov/press2007/0523whabirdflu.html" xmlns:xlink="http://www.w3.org/1999/xlink">http://geneva.usmission.gov/press2007/0523whabirdflu.html</ext-link>.
  </p>
 </fn>
 <fn id="Fn65">
  <label>65</label>
  <p id="Par94">World Health Organisation (
   <xref ref-type="bibr" rid="CR49">2005b</xref>, 1).
  </p>
 </fn>
 <fn id="Fn66">
  <label>66</label>
  <p id="Par95">Fidler, above n 33. Fidler provides a comprehensive legal analysis of the possible interpretations of related provisions of the IHR (
   <xref ref-type="bibr" rid="CR02">2005</xref>) and how these may or may not have applied to the Indonesian viral sovereignty claim.
  </p>
 </fn>
 <fn id="Fn67">
  <label>67</label>
  <p id="Par97">Ibid., 93.</p>
 </fn>
 <fn id="Fn68">
  <label>68</label>
  <p id="Par98">Gostin (
   <xref ref-type="bibr" rid="CR20">2014</xref>, 101).
  </p>
 </fn>
 <fn id="Fn69">
  <label>69</label>
  <p id="Par100">Zaki (
   <xref ref-type="bibr" rid="CR64">2012</xref>).
  </p>
 </fn>
 <fn id="Fn70">
  <label>70</label>
  <p id="Par101">Joseph et al. (
   <xref ref-type="bibr" rid="CR28">2013</xref>).
  </p>
 </fn>
 <fn id="Fn71">
  <label>71</label>
  <p id="Par102">Heymann and Rodier (
   <xref ref-type="bibr" rid="CR23">2004</xref>).
  </p>
 </fn>
 <fn id="Fn72">
  <label>72</label>
  <p id="Par103">WHO Regional Office for the Eastern Mediterranean (
   <xref ref-type="bibr" rid="CR47">2018</xref>).
  </p>
 </fn>
 <fn id="Fn73">
  <label>73</label>
  <p id="Par104">World Health Organisation (
   <xref ref-type="bibr" rid="CR59">2017a</xref>).
  </p>
 </fn>
 <fn id="Fn74">
  <label>74</label>
  <p id="Par105">World Health Organisation (
   <xref ref-type="bibr" rid="CR61">2018</xref>).
  </p>
 </fn>
 <fn id="Fn75">
  <label>75</label>
  <p id="Par107">Bartholomeus Leonardus Haagmans et al., ‘Patent WO 2014/045254 A2’.</p>
 </fn>
 <fn id="Fn76">
  <label>76</label>
  <p id="Par109">Fidler (
   <xref ref-type="bibr" rid="CR18">2013</xref>).
  </p>
 </fn>
 <fn id="Fn77">
  <label>77</label>
  <p id="Par112">Margaret Chan quoted in Edward Hammond, 
   <italic>Material Transfer Agreement Underlying the Controversy over Patent Rights and the Middle Eastern Respiratory Syndrome Virus</italic> (2013) Third World Network, 
   <ext-link ext-link-type="uri" xlink:href="http://www.twn.my/title2/biotk/2013/biotk130502.htm" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.twn.my/title2/biotk/2013/biotk130502.htm</ext-link>.
  </p>
 </fn>
 <fn id="Fn78">
  <label>78</label>
  <p id="Par114">If true, this would constitute a violation of Article 6.1 of IHR (
   <xref ref-type="bibr" rid="CR02">2005</xref>). World Health Organisation (
   <xref ref-type="bibr" rid="CR49">2005b</xref>), above n 64.
  </p>
 </fn>
 <fn id="Fn79">
  <label>79</label>
  <p id="Par115">Youde (
   <xref ref-type="bibr" rid="CR63">2015</xref>).
  </p>
 </fn>
 <fn id="Fn80">
  <label>80</label>
  <p id="Par116">Heymann et al. (
   <xref ref-type="bibr" rid="CR24">2016</xref>).
  </p>
 </fn>
 <fn id="Fn81">
  <label>81</label>
  <p id="Par118">World Health Organisation (
   <xref ref-type="bibr" rid="CR51">2014</xref>).
  </p>
 </fn>
 <fn id="Fn82">
  <label>82</label>
  <p id="Par119">World Health Organisation (
   <xref ref-type="bibr" rid="CR56">2016a</xref>).
  </p>
 </fn>
 <fn id="Fn83">
  <label>83</label>
  <p id="Par120">Spengler et al. (
   <xref ref-type="bibr" rid="CR43">2016</xref>).
  </p>
 </fn>
 <fn id="Fn84">
  <label>84</label>
  <p id="Par121">Abayomi et al. (
   <xref ref-type="bibr" rid="CR1">2016</xref>).
  </p>
 </fn>
 <fn id="Fn85">
  <label>85</label>
  <p id="Par123">Heymann et al. above n 79.</p>
 </fn>
 <fn id="Fn86">
  <label>86</label>
  <p id="Par125">Costello and Zumla (
   <xref ref-type="bibr" rid="CR13">2000</xref>).
  </p>
 </fn>
 <fn id="Fn87">
  <label>87</label>
  <p id="Par126">Heymann et al. above n 79, 1505.</p>
 </fn>
 <fn id="Fn88">
  <label>88</label>
  <p id="Par127">Costello and Zumla, above n 85.</p>
 </fn>
 <fn id="Fn89">
  <label>89</label>
  <p id="Par129">Conton (
   <xref ref-type="bibr" rid="CR12">2017</xref>)
  </p>
 </fn>
 <fn id="Fn90">
  <label>90</label>
  <p id="Par130">Ibid., 143.</p>
 </fn>
 <fn id="Fn91">
  <label>91</label>
  <p id="Par132">Schopper et al. (
   <xref ref-type="bibr" rid="CR38">2017</xref>)
  </p>
 </fn>
 <fn id="Fn92">
  <label>92</label>
  <p id="Par134">Abayomi et al., ‘African Civil Society Initiatives to Drive a Biobanking, Biosecurity and Infrastructure Development Agenda in the Wake of the West African Ebola Outbreak’ 1. 
   <ext-link ext-link-type="uri" xlink:href="http://www.panafrican-med-journal.com/content/article/24/270/full/%250A%c2%a9" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.panafrican-med-journal.com/content/article/24/270/full/%0A©</ext-link>.
  </p>
 </fn>
 <fn id="Fn93">
  <label>93</label>
  <p id="Par135">Georgetown Global (
   <xref ref-type="bibr" rid="CR19">2018</xref>).
  </p>
 </fn>
 <fn id="Fn94">
  <label>94</label>
  <p id="Par136">Abayomi et al., above n 91, 3; World Health Organisation (
   <xref ref-type="bibr" rid="CR54">2015c</xref>).
  </p>
 </fn>
 <fn id="Fn95">
  <label>95</label>
  <p id="Par137">World Health Organisation, above n 93.</p>
 </fn>
 <fn id="Fn96">
  <label>96</label>
  <p id="Par138">Ibid.</p>
 </fn>
 <fn id="Fn97">
  <label>97</label>
  <p id="Par140">Ibid.</p>
 </fn>
 <fn id="Fn98">
  <label>98</label>
  <p id="Par142">Hinterberger and Porter (
   <xref ref-type="bibr" rid="CR25">2015</xref>).
  </p>
 </fn>
 <fn id="Fn99">
  <label>99</label>
  <p id="Par143">Bollinger, above n 9, 7.</p>
 </fn>
 <fn id="Fn100">
  <label>100</label>
  <p id="Par144">Hinterberger and Porter, above n 97, 378.</p>
 </fn>
 <fn id="Fn101">
  <label>101</label>
  <p id="Par145">Viral sovereignty may even be extended to virus samples collected prior to the entry into force of the CBD in 1993, see Rourke (
   <xref ref-type="bibr" rid="CR37">2018</xref>).
  </p>
 </fn>
 <fn id="Fn102">
  <label>102</label>
  <p id="Par147">World Health Organisation (
   <xref ref-type="bibr" rid="CR57">2016b</xref>, p 1).
  </p>
 </fn>
 <fn id="Fn103">
  <label>103</label>
  <p id="Par148">Cheng et al. (
   <xref ref-type="bibr" rid="CR11">2016</xref>).
  </p>
 </fn>
 <fn id="Fn104">
  <label>104</label>
  <p id="Par149">Note that Brazil is not party to the Nagoya Protocol. See 
   <ext-link ext-link-type="uri" xlink:href="https://www.cbd.int/countries/default.shtml?country=br" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cbd.int/countries/default.shtml?country=br</ext-link>.
  </p>
 </fn>
 <fn id="Fn105">
  <label>105</label>
  <p id="Par150">Brazilian Association of the Cosmetics Toiletry and Fragrance Industry (
   <xref ref-type="bibr" rid="CR6">2018</xref>).
  </p>
 </fn>
 <fn id="Fn106">
  <label>106</label>
  <p id="Par151">Khaled (
   <xref ref-type="bibr" rid="CR30">2016</xref>).
  </p>
 </fn>
 <fn id="Fn107">
  <label>107</label>
  <p id="Par152">Ibid.</p>
 </fn>
 <fn id="Fn108">
  <label>108</label>
  <p id="Par155">World Health Organisation (
   <xref ref-type="bibr" rid="CR60">2017b</xref>).
  </p>
 </fn>
 <fn id="Fn109">
  <label>109</label>
  <p id="Par156">Majid (
   <xref ref-type="bibr" rid="CR32">2018</xref>).
  </p>
 </fn>
 <fn id="Fn110">
  <label>110</label>
  <p id="Par158">Baumgaertner (
   <xref ref-type="bibr" rid="CR3">2018</xref>).
  </p>
 </fn>
 <fn id="Fn111">
  <label>111</label>
  <p id="Par159">See Cullet (
   <xref ref-type="bibr" rid="CR14">2001</xref>).
  </p>
 </fn>
 <fn id="Fn112">
  <label>112</label>
  <p id="Par161">See comments by Jonathan Van Tam and Ian Jones, Majid, above n 108.</p>
 </fn>
 <fn id="Fn113">
  <label>113</label>
  <p id="Par162">PIP Framework 2011, Arts. 5.4.1 and Annex 1 (SMTA 1), and 5.4.2 and Annex 2 (SMTA 2).</p>
 </fn>
 <fn id="Fn114">
  <label>114</label>
  <p id="Par164">World Health Organisation (
   <xref ref-type="bibr" rid="CR55">2015d</xref>).
  </p>
 </fn>
 <fn id="Fn115">
  <label>115</label>
  <p id="Par165">Modjarrad et al. (
   <xref ref-type="bibr" rid="CR33">2016</xref>).
  </p>
 </fn>
 <fn id="Fn116">
  <label>116</label>
  <p id="Par166">
   <italic>International Health Regulations</italic> (
   <xref ref-type="bibr" rid="CR02">2005</xref>) Art. 6.
  </p>
 </fn>
 <fn id="Fn117">
  <label>117</label>
  <p id="Par167">World Health Organisation, above n 10.</p>
 </fn>
 <fn id="Fn118">
  <label>118</label>
  <p id="Par169">Ibid. This stance was repeated in World Health Organisation (
   <xref ref-type="bibr" rid="CR58">2016c</xref>).
  </p>
 </fn>
 <fn id="Fn119">
  <label>119</label>
  <p id="Par171">World Health Organisation, above n 113.</p>
 </fn>
 <fn id="Fn120">
  <label>120</label>
  <p id="Par174">Modjarrad et al., above n 114, 3–4.</p>
 </fn>
 <fn id="Fn121">
  <label>121</label>
  <p id="Par178">World Health Organisation (
   <xref ref-type="bibr" rid="CR58">2016c</xref>), above n 117, 238.
  </p>
 </fn>
 <fn id="Fn122">
  <label>122</label>
  <p id="Par181">Ibid., 239.</p>
 </fn>
 <fn id="Fn123">
  <label>123</label>
  <p id="Par185">Kamradt-Scott and Lee (
   <xref ref-type="bibr" rid="CR29">2011</xref>).
  </p>
 </fn>
 <fn id="Fn124">
  <label>124</label>
  <p id="Par186">This quote is from ibid. 832 where the authors are specifically referring to the inequalities of “the existing market-based political economy surrounding influenza vaccine and procurement”, but the term is quoted here as it applies equally well to the broader structural inequalities of global health preparedness and response.</p>
 </fn>
 <fn id="Fn125">
  <label>125</label>
  <p id="Par187">Bollinger, above n 9, 22.</p>
 </fn>
 <fn id="Fn126">
  <label>126</label>
  <p id="Par189">Hinterberger and Porter, above n 97, 372.</p>
 </fn>
 <fn id="Fn127">
  <label>127</label>
  <p id="Par190">There are various initiatives to address this practice, see e.g. the prepublication data sharing recommendations of the Toronto International Data Release Workshop, where “attendees endorsed the value of rapid pre-publication data release for large reference datasets in biology and medicine that have broad utility and agreed that pre-publication data release should go beyond genomics and proteomics studies to other datasets”. Toronto International Data Release Workshop Authors, ‘Prepublication Data Sharing’ (2009) 461 
   <italic>Nature</italic> 168, 168.
  </p>
 </fn>
 <fn id="Fn128">
  <label>128</label>
  <p id="Par191">Hurlbut, above n 62, 10.</p>
 </fn>
 <fn id="Fn129">
  <label>129</label>
  <p id="Par192">Centers for Disease Control and Prevention (
   <xref ref-type="bibr" rid="CR10">2016</xref>).
  </p>
 </fn>
 <fn id="Fn130">
  <label>130</label>
  <p id="Par194">Heymann et al., above n 79, 1505.</p>
 </fn>
 <fn id="Fn131">
  <label>131</label>
  <p id="Par195">Eccleston-Turner (
   <xref ref-type="bibr" rid="CR16">2017</xref>), Rourke, ‘Access by Design, Benefits If Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework’s Standard Material Transfer Agreements’ 
   <italic>Milbank Quaterly</italic> (
   <xref ref-type="bibr" rid="CR01">2019</xref>).
  </p>
 </fn>
 <fn id="Fn132">
  <label>132</label>
  <p id="Par197">Carter (
   <xref ref-type="bibr" rid="CR9">2010</xref>).
  </p>
 </fn>
 <fn id="Fn133">
  <label>133</label>
  <p id="Par198">Ibid.</p>
 </fn>
</fn-group>
